{"analyses":[{"groupDescription":"Treatment comparison between the pexidartinib and placebo groups at Week 25","groupIds":["OG000","OG001"],"nonInferiorityComment":"Treatment comparison analysis","nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Fisher's Exact Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9"},{"groupId":"OG001","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8"},{"groupId":"OG001","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7"},{"groupId":"OG001","value":"0"}]}],"title":"Response (CR or PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Complete response (CR) and partial response (PR) were assessed using tumor volume score (TVS). A CR was defined as disappearance of all tumors and a PR was defined as at least a 30% decrease in the sum of diameters of target tumors using the baseline sum diameters as the reference. TVS is a semi-quantitative MRI scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor.","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG000","title":"Pexidartinib Part 1"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks Placebo: Placebo capsule matching Pexidartinib capsule for oral administration.","id":"OG001","title":"Placebo Part 1"}],"paramType":"NUMBER","populationDescription":"Best overall response was assessed in the ITT population.","reportingStatus":"POSTED","timeFrame":"Week 25","title":"Percentage of Participants With Symptomatic, Locally Advanced Tenosynovial Giant Cell Tumor (TGCT) Achieving Complete or Partial Response Based on Tumor Volume Score (TVS) After Receiving Pexidartinib Compared With Those on Placebo at Week 25","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}